transcranial magnetic stimulation: Individualized transcranial magnetic stimulation of targets based on the association between the orbitofrontal cortex and the functional activity of the habenula .
Study summary
Thirty depressed patients will be recruited to select individualized transcranial magnetic stimulation targets based on individual orbital frontal cortex and habenula functional activity connectivity for 10 or 20 treatments to assess the efficacy and safety of this intervention
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* Gender is not limited, age 18～60 years old;
* Comply with the diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) of the United States of America;
* Hamilton rating scale for depression (HAMD) 17-item score ≥ 18;
* The medication/psychotherapy received by the subject prior to the start of the study remained stable for at least 4 weeks .
Exclusion Criteria:
* History of serious somatic diseases or diseases that may affect the central nervous system (e.g., tumors, syphilis, etc.);
* Neurological disorders or risk of seizures, such as previous craniosynostosis, head trauma, alcoholism, abnormal electroencephalograms, MRI evidence of structural abnormalities in the brain, or family history of epilepsy;
* Patients with bipolar disorder and depression due to other psychiatric disorders (e.g., psychoactive and non-dependent substances);
* Contraindications to MRI scanning or transcranial magnetic stimulation therapy, such as metal or electronic devices placed in the body (intracranial metal foreign bodies, cochlear implants, pacemakers and stents and other metal foreign bodies), space phobia;
* People with psychotic symptoms requiring joint application of antipsychotic drugs;
* Those with high risk of suicide, or those who have already committed suicide or serious self-injury behavior requiring urgent intervention;
* Those who are pregnant, breastfeeding or planning to become pregnant during the trial;
* Other conditions judged by the investigator to be unsuitable as research subjects.
Primary outcome measure(s)
Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores from baseline to treatment day 10 — Baseline and treatment day 10 The Montgomery-Asberg Depression Rating Scale (MADRS) is a widely used clinical assessment tool designed to measure the severity of depressive symptoms.The MADRS consists of 10 items, each of which addresses a different aspect of depression, such as low mood, loss of interest, sleep disorders, appetite, concentration, fatigue, inability to feel pleasure, pessimistic thinking, and suicidal ideation. Each item is scored according to the severity of symptoms, ranging from 0 to 6, with a total score ranging from 0-60, with higher scores indicating more severe depressive symptoms.
Change = (treatment day 10 Score -Baseline Score).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.